Advancing its core technology offering, Equiva announced a major upgrade to its health relationship management (HRM) platform, an omnichannel SaaS offering that helps healthcare organizations develop and retain long-term customer relationships. The enhancements improve user experience, data collection, reporting, device tracking and extensibility.
“Moving to a more customer-centric model is imperative for healthcare providers,” said Equiva CEO Nir Altman. “Our HRM environment bridges data analytics with education and behavioral science-driven methodologies to purposefully mobilize intelligence-driven action among consumers, patients, their loved ones, and members of the care team.”
Equiva developed its HRM platform to help HCOs more cohesively leverage digital engagement strategies to strengthen relationships with existing patients and attract new customers. “We blend unique aspects of patient engagement, care management, and marketing capabilities into our digital environment, all within the framework of improving clinical outcomes and financial results.”
Equiva tablet, mobile app, kiosks, television, digital signage and remote patient monitoring solutions support strategic initiatives via thousands of deployments across hundreds of leading healthcare organizations including Mount Sinai, Northwell, Providence, Hackensack, UNC Health and others.
To read more, click here.
Healthmine‘s Health Risk Assessment offering has received Wellness & Health Promotion certification in Health Appraisal after a rigorous review by The National Committee for Quality Assurance (NCQA). This accomplishment is the result of Healthmine’s dedicated team continuously optimizing its digital technology to meet NCQA’s high standards and provide clients with the best tools for collecting self-reported member data.
To read more, click here.
Digital health company Carrum Health has incorporated metrics on patient outcomes and procedure appropriateness into its Centers of Excellence (COE) platform. Combining its seven years of real-world patient outcome data with comprehensive commercial claims, clinical and Medicare data sets, integrated with a machine learning platform, Carrum Health can now offer unprecedented insights into the three most impactful aspects of quality: appropriateness, functional outcomes and traditional readmission/complication metrics.
Carrum Health’s algorithm is the only quality tool available in the market that factors in appropriateness and patient reported outcomes, while utilizing procedure-specific quality metrics developed by experts in each of its COE surgical and non-surgical specialties.
“As a physician, it’s important to partner with organizations that share our commitment to high quality patient care,” said Nicholas Theodore, M.D., director of the Neurosurgical Spine Center and professor of Neurosurgery at Johns Hopkins University School of Medicine. “By measuring quality as well as appropriateness, Carrum Health is setting a higher standard by creating a system of measurement and enabling patients to identify best-in-class providers. At the same time, it allows providers to focus on providing care to patients who truly need it, ultimately driving better outcomes.”
NeuroOne, a medical technology company developing high-definition, minimally invasive thin-film electrodes for the diagnosis and treatment of neurological conditions, has appointed a Vice President of Quality Control and Regulatory Affairs.
Chad Wilhelmy previously served in a similar role with HLT Medical, a subsidiary of the Bracco Group.
To read more, click here.
Prellis Biologics has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol-Myers Squibb (BMS). This is the first human-based antibody discovery being implemented in the pharmaceutical industry, according to the company.
EXIS from Prellis is the first fully synthetic, animal-free, functional human immune system that can break tolerance mechanisms in vitro to create high affinity human antibodies targeting human proteins; advanced holographic printing technology rapidly matches and replicates human organ and tissue structures. To date, Prellis has developed antibodies responsive to SARS-CoV-2, Influenza A and Marburg Hemorrhagic Fever.
Under the terms of the agreement, Prellis and BMS will collaborate on the generation of human antibody libraries for select targets. Prellis will receive from BMS an undisclosed up-front payment, funding for research activities, development and sales milestones, as well as royalties for licensed antibodies.
To read more, click here.
Picture: akindo, Getty Images
